|
KMID : 0357920130470020107
|
|
Korean Journal of Pathology
2013 Volume.47 No. 2 p.107 ~ p.115
|
|
|
EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
|
|
Hwangbo Won
Lee Jeong-Hyeon
Ahn Sang-Jeong
Kim Seo-Jin
Park Kyong-Hwa
Kim Chul-Hwan
Kim In-Sun
|
|
|
Abstract
|
|
|
|
Background: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment. Methods: A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification. Results: EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6? (CK5/6?) group, 11.2% of the HER-2?, EGFR+, CK5/6? group, and 19.1% of the HER-2?, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki- 67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6. Conclusions: EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.
|
|
|
KEYWORD
|
|
|
Breast neoplasms, Receptor, epidermal growth factor, Gene amplification, Protein expression
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|